Cargando…

Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis

Background: The drug selection of radical surgery (RS), with hyperthermic intraperitoneal chemotherapy (HIPEC), in pT4 colorectal cancer (CRC) remains controversial. Methods: Adverse events after HIPEC were estimated by common terminology criteria for adverse events version 5.0. The efficacy was eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Xikai, Lin, Yao, Shen, Chu, Li, Yuan, Xiang, Fan, Ruan, Tuo, Zeng, Xinyu, Lv, Jianbo, Tao, Kaixiong, Wu, Chuanqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955354/
https://www.ncbi.nlm.nih.gov/pubmed/36826075
http://dx.doi.org/10.3390/curroncol30020114
_version_ 1784894327077470208
author Guo, Xikai
Lin, Yao
Shen, Chu
Li, Yuan
Xiang, Fan
Ruan, Tuo
Zeng, Xinyu
Lv, Jianbo
Tao, Kaixiong
Wu, Chuanqing
author_facet Guo, Xikai
Lin, Yao
Shen, Chu
Li, Yuan
Xiang, Fan
Ruan, Tuo
Zeng, Xinyu
Lv, Jianbo
Tao, Kaixiong
Wu, Chuanqing
author_sort Guo, Xikai
collection PubMed
description Background: The drug selection of radical surgery (RS), with hyperthermic intraperitoneal chemotherapy (HIPEC), in pT4 colorectal cancer (CRC) remains controversial. Methods: Adverse events after HIPEC were estimated by common terminology criteria for adverse events version 5.0. The efficacy was evaluated using overall survival (OS) and recurrence-free rate (RFR). Propensity score matching (PSM) was used to reduce the influence of confounders between Mitomycin and Lobaplatin groups. Results: Of the 146 patients, from April 2020 to March 2021, 47 were managed with mitomycin and 99 with lobaplatin. There was no significant difference in the incidence of all adverse events between the two groups after PSM. OS and RFR were not significantly different between the two groups at 22 months (p = 0.410; p = 0.310). OS and RFR of the two groups also showed no significant difference for patients with T4a or T4b stage, tumor size < or ≥ 5 cm. Among patients with colon cancer, RFR at 22 months of the two groups was significantly different (100.0% vs. 63.2%, p = 0.028). Conclusions: In summary, the safety of mitomycin and lobaplatin for HIPEC was not different. Compared with lobaplatin, mitomycin for HIPEC after RS could benefit patients with colon cancer in RFR.
format Online
Article
Text
id pubmed-9955354
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99553542023-02-25 Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis Guo, Xikai Lin, Yao Shen, Chu Li, Yuan Xiang, Fan Ruan, Tuo Zeng, Xinyu Lv, Jianbo Tao, Kaixiong Wu, Chuanqing Curr Oncol Article Background: The drug selection of radical surgery (RS), with hyperthermic intraperitoneal chemotherapy (HIPEC), in pT4 colorectal cancer (CRC) remains controversial. Methods: Adverse events after HIPEC were estimated by common terminology criteria for adverse events version 5.0. The efficacy was evaluated using overall survival (OS) and recurrence-free rate (RFR). Propensity score matching (PSM) was used to reduce the influence of confounders between Mitomycin and Lobaplatin groups. Results: Of the 146 patients, from April 2020 to March 2021, 47 were managed with mitomycin and 99 with lobaplatin. There was no significant difference in the incidence of all adverse events between the two groups after PSM. OS and RFR were not significantly different between the two groups at 22 months (p = 0.410; p = 0.310). OS and RFR of the two groups also showed no significant difference for patients with T4a or T4b stage, tumor size < or ≥ 5 cm. Among patients with colon cancer, RFR at 22 months of the two groups was significantly different (100.0% vs. 63.2%, p = 0.028). Conclusions: In summary, the safety of mitomycin and lobaplatin for HIPEC was not different. Compared with lobaplatin, mitomycin for HIPEC after RS could benefit patients with colon cancer in RFR. MDPI 2023-01-21 /pmc/articles/PMC9955354/ /pubmed/36826075 http://dx.doi.org/10.3390/curroncol30020114 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Guo, Xikai
Lin, Yao
Shen, Chu
Li, Yuan
Xiang, Fan
Ruan, Tuo
Zeng, Xinyu
Lv, Jianbo
Tao, Kaixiong
Wu, Chuanqing
Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis
title Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis
title_full Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis
title_fullStr Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis
title_full_unstemmed Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis
title_short Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis
title_sort comparative study of short-term efficacy and safety of mitomycin versus lobaplatin for hyperthermic intraperitoneal chemotherapy after radical surgery in colorectal cancer with high-risk factors for peritoneal carcinomatosis: a propensity score matching analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955354/
https://www.ncbi.nlm.nih.gov/pubmed/36826075
http://dx.doi.org/10.3390/curroncol30020114
work_keys_str_mv AT guoxikai comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis
AT linyao comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis
AT shenchu comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis
AT liyuan comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis
AT xiangfan comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis
AT ruantuo comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis
AT zengxinyu comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis
AT lvjianbo comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis
AT taokaixiong comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis
AT wuchuanqing comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis